Veritas In Silico Inc

NEW
TSE:130A (Japan)  
円 448 +3 (+0.67%) Aug 21
At Loss
P/B:
2.08
Market Cap:
円 2.91B ($ 18.27M)
Enterprise V:
円 1.48B ($ 9.28M)
Volume:
29.30K
Avg Vol (2M):
19.73K
Trade In:

Business Description

Description
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs. The company operates a pipeline-type business model, currently focuses on nucleic acid drugs.
Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.92
Interest Coverage
No Debt
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
13.43
Distress
Grey
Safe
Beneish M-Score
-1.35
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate
-24.4
3-Year EBITDA Growth Rate
-43.9
3-Year EPS without NRI Growth Rate
-34.1
3-Year FCF Growth Rate
-11.1
3-Year Book Growth Rate
4

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
78.05
9-Day RSI
69.19
14-Day RSI
63.29
3-1 Month Momentum %
0.25
6-1 Month Momentum %
-15.51
12-1 Month Momentum %
-43.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
16.46
Quick Ratio
16.33
Cash Ratio
15.72
Days Sales Outstanding
22.3

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-1
Name Current Vs Industry Vs History
Operating Margin %
-516.26
Net Margin %
-709.82
EBITDA Margin %
-497.51
FCF Margin %
-389.66
OCF Margin %
-352.82
ROE %
-34.77
ROA %
-32.56
ROIC %
-647.52
3-Year ROIIC %
2754.1
ROC (Joel Greenblatt) %
-2665.89
ROCE %
-25.11
Years of Profitability over Past 10-Year
1

Financials

TSE:130A's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Veritas In Silico Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil 円) 84.82
EPS (TTM) (円) -92.81
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % 24.68
14-Day RSI 63.29
14-Day ATR (円) 17.605447
20-Day SMA (円) 415.6
12-1 Month Momentum % -43.87
52-Week Range (円) 390 - 793
Shares Outstanding (Mil) 6.49

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Veritas In Silico Inc Filings

Filing Date Document Date Form
No Filing Data

Veritas In Silico Inc Stock Events

Financials Calendars
Event Date Price (円)
No Event Data

Veritas In Silico Inc Frequently Asked Questions

What is Veritas In Silico Inc(TSE:130A)'s stock price today?
The current price of TSE:130A is 円448.00. The 52 week high of TSE:130A is 円793.00 and 52 week low is 円390.00.
When is next earnings date of Veritas In Silico Inc(TSE:130A)?
The next earnings date of Veritas In Silico Inc(TSE:130A) is .
Does Veritas In Silico Inc(TSE:130A) pay dividends? If so, how much?
Veritas In Silico Inc(TSE:130A) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on Veritas In Silico Inc

No articles.